Secreted gliomedin is a perinodal matrix component of peripheral nerves by Eshed, Yael et al.
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
I
O
L
O
G
Y
JCB: ARTICLE
© The Rockefeller University Press    $15.00
The Journal of Cell Biology, Vol. 177, No. 3, May 7, 2007 551–562
http://www.jcb.org/cgi/doi/10.1083/jcb.200612139
JCB 551
Introduction
The presence of voltage-gated Na
+ channels at the nodes of 
Ranvier ensures fast saltatory propagation of action poten-
tials in myelinated nerves. The accumulation of these channels 
at nodes is tightly regulated by the overlaying myelinating 
Schwann cells (Poliak and Peles, 2003; Salzer, 2003; Schafer 
and Rasband, 2006). In the peripheral nervous system (PNS), 
the nodal axolemma is contacted by an ordered array of micro-
villi that project radially from the outer collar of two adja-
cent myelinating Schwann cells. These Schwann cell microvilli 
are embedded within a poorly defi  ned fi  lamentous matrix (i.e., 
the gap substance) that was referred to as the “cement disc” by 
Ranvier (Landon and Hall, 1976). The nodal gap substance 
consists of proteoglycans and nonsulfated mucopolysaccha-
rides, which contribute to the ability of a wide variety of me-
tallic cations to label the nodes of Ranvier (Zagoren, 1984). 
Proteoglycans that are present at peripheral nodes include 
versican (Apostolski et al., 1994; Melendez-Vasquez et al., 
2005), NG2 (Martin et al., 2001), and syndecans (Goutebroze 
et al., 2003; Melendez-Vasquez et al., 2005), as well as hyaluronic 
acid and its binding protein hyaluronectin, which are associ-
ated with proteoglycans in the ECM (Apostolski et al., 1994; 
Delpech et al., 1982). Several ECM and ECM-associated 
proteins are also enriched at PNS nodes, such as collagen 
α4(V) (Melendez-Vasquez et al., 2005), laminin α2β1γ1 and 
α5β1γ1 (Occhi et al., 2005), dystroglycan, and some members 
of the dystrophin–glycoprotein complex (Occhi et al., 2005; 
Saito et al., 2003). Schwann cell–specifi  c ablation of dystro-
glycan (Saito et al., 2003), and to a lesser extent of laminin γ1 
(Occhi et al., 2005), causes disruption of microvillar organiza-
tion and reduction in nodal Na
+ channel clustering, suggesting 
that the microvilli play a direct role in node assembly. This 
notion is further supported by observations demonstrating 
that Schwann cell microvillar processes align with nascent 
nodes (Tao-Cheng and Rosenbluth, 1983; Melendez-Vasquez 
et al., 2001).
At the nodal axolemma, Na
+ channels associate with two 
cell adhesion molecules (CAMs), NrCAM and the 186-kD 
isoform of neurofascin (Davis et al., 1996). Growing evidence 
suggests that during development, Na
+ channels are recruited 
to clusters containing these axonodal CAMs that were fi  rst 
positioned by glial processes (Lambert et al., 1997; Lustig et al., 
2001; Custer et al., 2003; Eshed et al., 2005; Sherman et al., 
2005; Koticha et al., 2006; Schafer et al., 2006). Neurofascin 
and NrCAM interact with gliomedin, which is concentrated at 
the Schwann cell microvilli (Eshed et al., 2005). During mye-
lination, gliomedin accumulates at the edges of myelinating 
Schwann cells, where it is associated with early clusters of 
Na
+ channels. In myelinating cultures, both the expression 
and correct localization of gliomedin are essential for node 
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formation. Gliomedin is a type II transmembrane protein that 
is characterized by the presence of olfactomedin and collagen 
domains in its extracellular region, a domain organization 
shared by members of a specifi  c subgroup of the olfacto-
medin proteins, termed colmedins (Loria et al., 2004). In addition, 
gliomedin contains a putative α- helical,  coiled-coil sequence at 
its juxtamembrane region, which serves as an oligomerization 
motif in collagenous transmembrane proteins (Latvanlehto 
et al., 2003; Franzke et al., 2005). The olfactomedin domain 
of gliomedin was shown to mediate its interaction with neuro-
fascin and NrCAM (Eshed et al., 2005). The aggregation of 
this domain using a secondary antibody was suffi  cient to in-
duce nodelike clusters along the axons of isolated dorsal root 
ganglion (DRG) neurons. These observations led us to pro-
pose that the focal presentation of gliomedin to the axon dur-
ing myelination causes the initial clustering of the axonodal 
CAMs into higher-order oligomers, which facilitates the re-
cruitment of ankyrin G and Na
+ channels (Eshed et al., 2005). 
We report that gliomedin is cleaved from the cell surface 
by a furin protease, and then assembles into high–molecular 
weight multimers and incorporates into the ECM by binding 
to HSPGs. We propose that these unique features endow glio-
medin its ability to cluster the axonodal CAMs, thereby facili-
tating node formation.
Results
Differential binding of gliomedin to DRG 
neurons and Schwann cells
We have previously shown that the OLF domain of gliomedin 
mediates it interaction with axonal neurofascin and NrCAM 
(Eshed et al., 2005). To examine the existence of additional lig-
ands for gliomedin in peripheral nerves, we used a soluble Fc-
fusion protein containing its extracellular domain but lacking its 
OLF domain (COL-Fc) in binding experiments on mixed DRG 
neurons/Schwann cell cultures (Fig. 1, A and B). Whereas OLF-
Fc bound to neurons as expected, COL-Fc binding was detected 
to a subpopulation of Schwann cells that were aligned with axons. 
Binding experiments using cultures of rat Schwann cells, re-
vealed that both COL-Fc (Fig. 1 E) and an Fc-fusion protein 
containing the entire extracellular domain of gliomedin (ECD-
Fc; Fig. 1 C) labeled the cells, as well as areas between adjacent 
cells, suggesting that they interact with Schwann cell ECM. In 
contrast, OLF-Fc did not bind to Schwann cells (Fig. 1 D). To 
determine whether COL-Fc interacts with Schwann cell ECM, 
we have grown Schwann cells in the presence of ascorbate, 
which induces the formation of ECM fi  brils and basal lamina–
like structures (Eldridge et al., 1989). In ascorbate-treated 
Schwann cells, binding of COL-Fc was detected to the cell 
Figure 1.  Distinct domains of gliomedin me-
diate its interaction with neurons and Schwann 
cell ECM. The domain organization of glio-
medin and the Fc-fusion proteins used in bind-
ing experiments are depicted at the top. TM, 
transmembrane domain; cc, coiled-coil; NTR, 
N-  terminal region; COL, interrupted collagen 
repeats; OLF, olfactomedin domain. (A and B) 
Gliomedin interacts with both neurons and 
Schwann cells. Binding of OLF-Fc or COL-Fc to 
dissociated embryonic DRG cultures; Fc bind-
ing is shown in red, neurons were labeled with 
an antibody to βIII tubulin (Tuj1; green), and 
the nuclei of both neurons and Schwann cells 
were labeled with DAPI (blue). Note the bind-
ing of COL-Fc to a group of Schwann cells that 
are aligned with axons (arrowheads). At this 
stage of the culture, only a few neurons ex-
press neurofascin and bound OLF-Fc. (C–E) 
Interaction of gliomedin with Schwann cells. 
Binding ECD-Fc (containing the entire extra-
cellular domain of gliomedin), OLF-Fc, or COL-Fc 
(all in red) to cultured rat Schwann cells, as in-
dicated. Cells were labeled with Alexa Fluor 
488 phalloidin to detect actin (Act; green), 
and the nuclei were labeled with DAPI (blue). 
Note the robust binding of ECD-Fc and 
COL-Fc, but not of OLF-Fc in between the cells 
(arrowheads). (F) Interaction of gliomedin with 
Schwann cell ECM. Binding of COL-Fc (red) to 
ascorbic acid–treated culture of rat Schwann 
cells. Actin was labeled with Alexa Fluor 488 
phalloidin (Act; green) and the nuclei were 
labeled with DAPI (blue). COL-Fc bound to the 
cell surface, as well as to ECM deposits lo-
cated between the cells. (G) Before binding of 
COL-Fc and labeling as in C, the slides were 
washed using ammonium hydroxide and Triton 
X-100 to remove the cells. COL-Fc bound to 
ECM components that were still present on the slide after removal of the cells. (H and I) The same experiment was performed using cultured astrocytes. 
In contrast to Schwann cells, COL-Fc binding to astrocytes was only detected on the cell surface and was eliminated after removal of the cells. Bars: 
(C–E) 30 μm; (F–I) 15 μm.GLIOMEDIN IS A PERINODAL MATRIX COMPONENT • ESHED ET AL. 553
surface, as well as to ECM deposits located between the cells 
(Fig. 1 F). COL-Fc still bound these ECM deposits in cultures 
that were pretreated with ammonium hydroxide and Triton 
X-100, a procedure that completely removed the cells from the 
slide but left the ECM fi  brils intact (Fig. 1 G). To determine 
whether the interaction of COL-Fc with the ECM was specifi  c 
to Schwann cells, we  examined whether it binds astrocytes, 
which are known to accumulate similar ECM structures in cul-
ture (Ard and Bunge, 1988). As depicted in Fig. 1 (H and I), 
COL-Fc bound to the cell surface of astrocytes, but it did not 
bind to cell-free areas or to cultures pretreated with ammonium 
hydroxide and Triton X-100. These results demonstrate that the 
extracellular region of gliomedin contains distinct domains that 
mediate its interaction with both neurons and Schwann cells. 
They further suggest the existence of a novel glial ligand for 
gliomedin embedded within the Schwann cell ECM.
Gliomedin is found in both transmembrane 
and secreted forms
The domain organization of gliomedin is reminiscent of trans-
membrane collagens, all of which are type II transmembrane 
proteins that are cleaved from the cell membrane by furin-type 
endoprotease (Franzke et al., 2005). Hence, the ability of glio-
medin to bind ECM deposits that are not cell surface–associated 
raises the question of whether it is secreted from Schwann cells. 
To examine this possibility, we immunoprecipitated gliomedin 
from cell lysates and media of cultured Schwann cells using an 
antibody to the cytoplasmic tail (Ab836), or an antibody di-
rected to the olfactomedin domain (Ab320). As a control, we 
used human embryonic kidney (HEK)-293 cells that were trans-
fected with a C-terminal, myc-tagged, full-length gliomedin 
cDNA. Immunoblots were then performed using an antibody to 
myc tag or an antibody that recognizes a short peptide sequence 
between the collagen and the olfactomedin domain (Ab720; 
recognition sites of the various antibodies is schematically de-
picted in Fig. 2 C). Ab836 and Ab320 immunoprecipitated an 
89-kD protein from the lysates of Schwann cells that correspond 
to the transmembrane form of gliomedin (Fig. 2 A, middle). In 
transfected HEK-293 cells, the transmembrane form of glio-
medin appeared as a doublet consisting of the 89-kD and a weaker 
 92-kD band. In addition, Ab320 specifi  cally precipitated a 
91-kD protein from the medium of both cell types and a 45-kD 
protein from the transfected HEK-293 cells. The 45-kD protein 
was also detected in the medium of Schwann cells that were 
Figure 2.  Gliomedin is a secreted protein generated by proteolysis. (A) Secretion of gliomedin by cultured cells. Media conditioned by cultured Schwann cells 
or HEK-293 cells transfected with a full-length, myc-tagged gliomedin cDNA were subjected to immunoprecipitation using antibodies that recognize the 
N- (Ab836) or C-terminal (Ab320) region of gliomedin (the region each antibody recognizes is shown in B). Western blotting was done using an antibody that rec-
ognizes a peptide located between the COL and OLF domains (MAb94) or to myc tag, as indicated. The location of molecular weight marker is shown on the 
right. (B) Glycosylation of gliomedin. Gliomedin was immunoprecipitated with Ab320 from cell lysate or the medium of HEK-293 cells transfected with a full-
length, myc-tagged gliomedin cDNA. Washed immunocomplexes were incubated with N-Glycosidase F (PNGase) as indicated, separated on a 12% SDS gel, 
and immunoblotted with an antibody to myc tag. Note that the core protein of the secreted gliomedin form (62 kD) is smaller by  11 kD than the transmembrane 
form found in the cell lysate (73 kD). (C) Identiﬁ  cation of cleavage sites in gliomedin. (right) Western blot analysis of protein-A–puriﬁ  ed material from medium 
(CM) of HEK-293 cells expressing a C-terminal Fc-fusion protein of a full-length gliomedin, using an antibody to human Fc; the presence of the Fc adds 30 kD. 
A schematic presentation of the two gliomedin fragments isolated is depicted on the left, together with the domain organization of the protein, the location of 
the cleavage sites (arrowheads), and the regions recognized by the different antibodies. The second proteolytic cleavage site, which is located just N-terminal 
to the OLF domain (PNDD), was identiﬁ  ed by N-terminal sequencing, whereas the ﬁ  rst furin site (RNKR) within the NTR was identiﬁ  ed by mutagenesis. The loca-
tions of R91 and R94 are labeled with asterisks. Color frames mark the different domains (gray, transmembrane; purple, coiled coil; blue, collagen; red, olfacto-
medin). (D) Secretion of the extracellular domain of gliomedin requires cleavage at a furin site. The media or cell lysates of HEK293 expressing a full-length 
gliomedin (WT) or a mutant form in which arginines 91 and 94 were replaced with glycine and alanine, respectively (R91G94A), were analyzed by immuno-
precipitation using Ab320 and immunoblotting with MAb94 as indicated. Note the decreased amount of gliomedin present in the media and the increase in 
the amount of the 82-kD transmembrane form (upper band in the doublet) in the cell lysate. (E) Only a secreted gliomedin is detected at the nodes of Ranvier. 
Teased rat sciatic nerves were immunolabeled using the different antibodies to gliomedin (red) and an antibody to Caspr (green), as indicated. Bar, 5 μm.JCB • VOLUME 177 • NUMBER 3 • 2007  554
maintained in culture for longer periods of time (Fig. 2 A, right). 
Treatment of gliomedin immunocomplexes with N-glycosidase 
revealed that the core protein of the secreted form is smaller by 
 11 kD than the transmembrane protein (62 vs. 73 kD; Fig. 
2 B). This analysis demonstrates that gliomedin is secreted 
from Schwann cells as a major 91-kD and a minor 45-kD protein.
To directly determine the cleavage sites in gliomedin, we 
used an Fc-fusion protein in which the Fc region was fused to 
the C-terminal region of the full-length gliomedin. The ratio-
nale behind this approach was that because gliomedin is a type II 
transmembrane protein, cleavage of the protein should result 
in the release of an Fc-tagged protein to the medium, which 
could be purifi  ed using protein A agarose. Two distinct bands of 
 116 and 80 kD were purifi  ed from the medium of HEK-293 
expressing this construct and were subjected to N-terminal 
amino acid sequencing (Fig. 2 C). The N-terminal sequence of 
the lower band was identifi   ed  as  D D T L V  ,  which  corresponds  to 
position 278 of rat gliomedin (NP_852047), which is located 
just before the beginning of the olfactomedin domain. Despite 
several attempts, we were unable to obtain the N-terminal se-
quence of the larger band. Analyzing the amino acid sequence 
of gliomedin between the transmembrane and the collagen do-
mains (position 38–138) for functional sites using the Eukaryotic 
Linear Motif server (http://elm.eu.org/; Puntervoll et al., 
2003), revealed the presence of a putative furin cleavage site 
(RNKR) at position 91–94. To determine whether this proteo-
lytic site is important to the processing of gliomedin, we have 
constructed a mutant of the full-length gliomedin by replacing 
arginine at position 91 with glycine and arginine at position 94 
with alanine (R91G94A). This mutant was transfected to HEK-
293 cells, and the medium of these cells was analyzed 2 d later 
for the presence of gliomedin (Fig. 2 D). Mutating these argi-
nines caused a marked reduction in the secretion of gliomedin 
to the medium, and was accompanied by an accumulation of the 
92-kD transmembrane form in the cells. These results indicate 
that proteolytic cleavage of the mature 92-kD form by a furin-
like enzyme mediates the shedding of the extracellular domain 
of gliomedin from the cell surface. In addition, and less fre-
quently, another cleavage of the molecule at position 278 may 
occur, which separates the olfactomedin domain from the colla-
gen triplex. Immunolabeling of teased rat sciatic nerves demon-
strated a nodal staining of gliomedin using Ab320 and Ab720, 
but not when Ab836 was used (Ab836 does recognize glio-
medin in Schwann cells; see Fig. 6 L), demonstrating that only 
the extracellular domain of gliomedin was detected at the nodes 
(Fig. 2 E). Furthermore, the transmembrane form of gliomedin 
Figure 3.  Oligomerization and self-association 
of secreted gliomedin. (A) Ascorbic acid in-
duced the formation of gliomedin multimers. 
Schwann cells grown in the absence (−) or 
presence (+) of ascorbic acid were washed 
and incubated with the BS
3 cross-linker, as in-
dicated. Cell lysates were made and used to 
immunoprecipitate gliomedin with an antibody 
to the OLF domain, followed by immunoblot-
ting using MAb94. The location of gliomedin 
monomers (Mono) and high-molecular weight 
multimers (HMW) is indicated with arrows. 
(B) Lysates of BS
3-treated Schwann cells grown 
in the absence (−) or presence (+) of ascorbic 
acid were subjected to immunoprecipitation 
using an antibody directed to the OLF domain, 
followed by immunoblot analysis using an 
antibody directed to the cytoplasmic domain 
(836; left); the membrane was reblotted with 
MAb94 (right). Gliomedin multimers were 
  detected with Ab720, but not with Ab836. 
(C) Domain organization of gliomedin and the 
various Fc-fusion proteins used in D and E. TM, 
transmembrane domain; cc, coiled coil; NTR, 
N-terminal region; COL, interrupted collagen 
repeats; OLF, olfactomedin domain; ECDdCC, 
ECD lacking the coiled-coil domain; ECDdNTR, 
ECD lacking the NTR; Fc, constant region of 
human IgG. (D) Self-association of gliomedin. 
The indicated Fc-fusion proteins were used to 
precipitate proteins from lysates of HEK-293 
cells expressing a myc-tagged gliomedin (Glio-
medin) or a myc-tag PSD93, followed by immuno-
blotting with an antibody to myc tag. Note the 
reduction in the ability of ECDdCC and ECDdNTR 
to pull down myc-gliomedin. (E) Binding of the 
olfactomedin domain of gliomedin to neuro-
fascin requires its preclustering. The indicated 
Fc-fusion proteins were incubated either directly 
(Nonclustered) or after preincubation with an 
anti-Fc antibody (Preclustered) with COS7 cells expressing neurofascin 186 (NF186). Bound Fc was detected using Cy3-conjugated antibody to human Fc 
(red), and the expression of NF186 was determined using a speciﬁ  c antibody (green). The location of molecular weight markers in kilodaltons is shown in A, B, 
and D. Bar, 30 μm.GLIOMEDIN IS A PERINODAL MATRIX COMPONENT • ESHED ET AL. 555
was not detected at nascent nodes during their development at 
sites that were labeled with the antibodies to the extracellular 
domain (unpublished data). Thus, we concluded that the main 
form of gliomedin found at the nodes of Ranvier is the cleaved 
form that contains the entire extracellular domain, including its 
collagen and olfactomedin domains.
Ascorbic acid induces the multimerization 
of gliomedin
The presence of a protease-resistant collagen domain in glio-
medin indicates that it may assemble into homotrimers or higher-
order multimers after cleavage from the cell surface. To test this 
possibility, we immunoprecipitated gliomedin from Schwann 
cells that were grown in the absence or presence of ascorbate, 
which stimulates the deposition of fi  brillar collagen by Schwann 
cells (Chernousov et al., 1998). Under reducing conditions, 
only a monomeric form of gliomedin with an apparent molecu-
lar weight of 89 kD protein was detected in both untreated and 
ascorbic acid–treated cells (Fig. 3 A). However, in the presence 
of a chemical cross-linker (BS
3), only high-molecular weight 
multimers of gliomedin were detected in ascorbic acid–treated 
cells (Fig. 3 A). These multimers were detected using an anti-
body to the extracellular, but not to the cytoplasmic tail, of glio-
medin (Fig. 3 B, right). Collectively, these results demonstrate 
that ascorbate treatment of Schwann cells induced the secretion, 
cleavage, and oligomerization of gliomedin.
Multimerization of gliomedin is required 
for its interaction with axonodal CAMs
To determine which region in gliomedin mediates its self-
  association, we examined the ability of purifi  ed Fc-fusion proteins 
containing its entire extracellular domain (ECD-Fc), olfacto-
medin domain (OLF-Fc), ECD lacking the olfactomedin domain 
(COL-Fc), ECD lacking the coiled-coil domain (ECDdCC-Fc), 
and ECD lacking its N-terminal linker region (ECDdNTR) to 
precipitate a full-length myc-tagged gliomedin from transfected 
HEK-293 cells (Fig. 3 C). Similar amounts of the Fc-fusion 
proteins were used, as detected by immunoblotting with an 
  antibody to human Fc (unpublished data). As an additional 
  control, we used HEK-293 cells expressing a myc-tagged PSD93. 
Whereas ECD-Fc and COL-Fc specifi  cally pulled-down glio-
medin, ECDdCC-Fc was less effi  cient (estimated 50% reduction), 
Figure 4.  Gliomedin is incorporated into Schwann cells ECM. (A–C) Association of gliomedin with the ECM is induced by ascorbic acid. Rat Schwann cells 
were grown in the absence (DME) or the presence (Ascorbate) of ascorbic acid and immunolabeled with antibodies to gliomedin (A; red) and collagen 
α4(V) (B; green). The merged image is shown on the right (C). (D) Ascorbic acid increases the insolubility of gliomedin. Schwann cells grown in DME or in 
the presence of ascorbic acid were lysed in a modiﬁ  ed RIPA buffer (−) or RIPA buffer containing 1% SDS (+) as indicated. Cell lysates were cleared by cen-
trifugation, and the insoluble pellet was resuspended in sample buffer (Pellet). Gliomedin was immunoprecipitated from the supernatant (Lysate) using an 
antibody to the OLF domain (320). The isolated immunocomplexes and the insoluble pellets were resolved on an SDS gel and immunoblotted with MAb94. 
The location of a 100-kD molecular weight marker is shown in each gel. (E–G) Incorporation of gliomedin into ECM ﬁ  brils. Schwann cells grown in the 
presence of ascorbic acid to induce ECM formation were washed with PBS, or with PBS containing ammonium hydroxide and Triton X-100 to remove the 
cells before immunolabeling with antibodies to gliomedin (E; red) and laminin (F; green). The merged image is shown in G. Bars, 30 μm.JCB • VOLUME 177 • NUMBER 3 • 2007  556
and only a weak signal was obtained using ECDdNTR-Fc. 
OLF-Fc was unable to recognize and precipitate gliomedin (Fig. 
3 D). To further explore the functional signifi  cance of these obser-
vations, we examined whether self-association of gliomedin is 
required for its interaction with neurofascin and NrCAM. To 
this end, COS7 cells expressing neurofascin (NF186) were in-
cubated with the different Fc-fusion proteins as either dimers 
(i.e., caused by the presence of the Fc) or as multimers by pre-
clustering them with a secondary antibody to human Fc (Fig. 3 E). 
It was found that, in contrast to ECD-Fc and ECDdCC-Fc, 
which bound to NF186-expressing cells without preclustering, 
only multimeric forms of ECDdNTR-Fc and OLF-Fc were able 
to recognize neurofascin. Similar results were obtained using 
DRG neurons (unpublished data). Thus, although the olfacto-
medin domain of gliomedin mediates its direct interaction with 
the axonodal CAMs (Eshed et al., 2005), multimerization of the 
extracellular domain of gliomedin, which is conferred by other 
sequences present at the N-terminal region of the molecule, is 
essential for this interaction to take place.
Secreted gliomedin multimers are 
incorporated into the Schwann cell ECM
The observation that a secreted extracellular domain of glio-
medin can bind to Schwann cells, has prompted us to examine 
whether the endogenous gliomedin is incorporated into the 
Schwann cell ECM. Thus, we immunolabeled cultured rat 
Schwann cells with antibodies to gliomedin, together with anti-
bodies to the known components of Schwann cell ECM, lam-
inin (Fig. 4, E–G), and the α4(V) collagen chain (Fig. 4, A–C). 
In Schwann cells grown in the absence of ascorbic acid, glio-
medin was mostly present on the cell surface, whereas α4(V) 
immunoreactivity was detected on the cell surface and between 
the cells. Growing the cells in the presence of ascorbic acid for 
48 h resulted in a dramatic incorporation of gliomedin into fi  -
brillar ECM deposits, where it was found to be colocalized with 
α4(V), mainly in the larger fi  brils (Fig. 4, A–C). Similar results 
were obtained using antibodies to perlecan and the α1(V) chain 
of collagen (unpublished data). Previous studies have shown 
that after ascorbic acid treatment, α4(V) incorporates into 
detergent-insoluble ECM material (Chernousov et al., 1998). 
To examine whether gliomedin was incorporated into similar 
structures, we immunoprecipitated gliomedin from ascorbic 
acid–treated Schwann cells that were extracted with a modifi  ed 
RIPA buffer, or with a RIPA buffer containing 1% SDS (Fig. 
4 D). Cells grown in the absence of ascorbic acid were used as 
a control. Western blot analysis of these immunoprecipitants 
showed that the inclusion of SDS signifi  cantly increased the 
amount of gliomedin detected in the lysates of ascorbic acid–
treated cells, but had no effect on the immunorecovery of glio-
medin from untreated cells. A large amount of gliomedin was 
detected in the insoluble material obtained after the extraction 
of ascorbic acid–treated cells, with the modifi  ed RIPA buffer 
lacking SDS (Fig. 4 D, bottom), whereas the addition of SDS to 
the lysis buffer signifi  cantly reduced the amount of gliomedin 
in the insoluble pellet.
To ascertain that gliomedin was incorporated into Schwann 
cell ECM, cultures of Schwann cells grown in the presence of 
ascorbic acid were washed with ammonium hydroxide and 
Triton X-100 to remove the cells, and then immunolabeled us-
ing antibodies to gliomedin and laminin (Fig. 4, E–G). In non-
treated cultures, gliomedin immunoreactivity was detected on 
the surface of the cells, as well as in fi  brillar structures that were 
also labeled for laminin (top). After cell removal, most of the 
gliomedin immunoreactivity was associated with laminin-positive 
fi  brils, further supporting the conclusion that it is incorporated 
into the ECM network. Notably, the extracellular domain of 
neurofascin (NF155-Fc; NF155 and NF186 are used inter-
changeably, as they both bind gliomedin) bound to ECM depos-
its that remained after Schwann cell removal, demonstrating 
that this axonodal CAM still recognizes the ECM-incorporated 
multimers of gliomedin (Fig. 5 A). The binding of Fc-fusion 
proteins containing the extracellular domain of Necl1/Syn-
CAM3, which is a CAM that interacts with Schwann cells, was 
abolished after the removal of the cells (Fig. 5 C), demonstrat-
ing that the ammonium hydroxide and Triton X-100 wash used 
did not create nonspecifi  c Fc-binding sites on the slides. Finally, 
similar experiments done using rat astrocytes revealed that al-
though these cells secrete large quantities of gliomedin to their 
culture medium (not depicted), NF155-Fc binding was only de-
tected on the cell surface (Fig. 5 B), indicating that gliomedin 
was not incorporated into the ECM produced by these cells. 
This conclusion is further supported by the observation that the 
extracellular domain of gliomedin did not bind astrocyte ECM, 
which suggests that Schwann cells produce a specifi  c ECM li-
gand for gliomedin (Fig. 1 I). Collectively, these results demon-
strate that upon ascorbic acid treatment, gliomedin is secreted 
Figure 5.  Binding of neurofascin to ECM-bound glio-
medin. Ascorbic acid–treated cultures of rat Schwann cells 
(A and C) or astrocytes (B) were washed with PBS (top) or 
ammonium hydroxide and Triton X-100 to remove the 
cells (bottom). Slides were incubated with an Fc-fusion 
protein containing the extracellular domain of neurofascin 
(A and B; NF155-Fc), or the extracellular domain of Nectin-
like protein 1 (C; Necl1-Fc) coupled to Cy3-conjugated 
anti–human Fc antibody (red). Unbound material was 
washed away, and the cells were ﬁ  xed and stained with 
Alexa Fluor 488-phalloidin to detect actin (green) and 
with DAPI to visualize nuclei (blue). Bar, 30 μm.GLIOMEDIN IS A PERINODAL MATRIX COMPONENT • ESHED ET AL. 557
from the cells and forms high-molecular weight multimers that 
are entrapped in the Schwann cell ECM.
Association of gliomedin with 
Schwann cell ECM is mediated 
by heparan sulfate proteoglycans
At the perinodal space, gliomedin is concentrated on the 
Schwann cell microvilli (Eshed et al., 2005), which are em-
bedded in the proteoglycan-rich perinodal matrix. To examine 
whether the association of gliomedin with Schwann cells ECM 
is mediated by heparan sulfate proteoglycans (HSPGs), we used 
NF155-Fc as a specifi  c affi  nity reagent to detect gliomedin in 
ascorbate-treated Schwann cells that were incubated with heparin. 
As depicted in Fig. 6 A, in the absence of heparin, gliomedin 
was present on both the cell surface and in ECM deposits be-
tween adjacent cells. In cultures incubated for 30 min with hepa-
rin, gliomedin was released from the ECM and was only present 
on the cell surface (Fig. 6 B). The removal of gliomedin from 
Schwann cell ECM by heparin was even clearer using cultures 
that were prewashed with ammonium hydroxide and Triton 
X-100 to remove the cells (Fig. 6, C and D). In contrast to glio-
medin, heparin had no effect on the distribution of α4(V) (Fig. 6, 
E–J) or other Schwann cell ECM components, such as laminin 
(unpublished data). Immunolabeling with an antibody to the cyto-
plasmic domain of gliomedin indicated that, in heparin-treated 
Schwann cells, NF155-Fc bound to the transmembrane form of 
gliomedin present on the cell surface (Fig. 6, K–M).
The effi  cient removal of secreted gliomedin by heparin indi-
cates that its association with Schwann cells ECM requires HSPGs. 
To establish whether gliomedin interacts with HSPGs, we tested 
the effect of heparin on the binding of its extracellular domain 
(ECD-Fc) to Schwann cells. As depicted in Fig. 7, A–D, heparin 
completely inhibited the binding of ECD-Fc, suggesting that 
gliomedin binds to glycosaminoglycan side chains of HSPGs 
expressed by Schwann cells. To examine whether gliomedin 
binds directly to heparin, we incubated the Fc-fusion proteins 
containing the different domains of gliomedin with heparin-
Sepharose and detected the bound material by immuno  blotting 
with an antibody to human Fc (Fig. 7 E). As control, we used 
protein A beads, which precipitated all of the Fc-  fusions 
tested. The extracellular domain of gliomedin (ECD), as well 
as an ECD lacking the olfactomedin domain (COL), the 
coiled-coil domain (ECDdCC), or its N-terminal linker region 
(ECDdNTR), bound to the heparin affi  nity matrix. In contrast, 
neither the olfactomedin domain alone (OLF) nor an Fc-fusion 
containing the extracellular region of the gliomedin-related 
myocilin protein were able to bind heparin, indicating that the 
heparin-binding sequence in gliomedin is located outside its 
  olfactomedin domain. Collectively, our results demonstrate that 
the incorporation of gliomedin to Schwann cell ECM is medi-
ated by its binding to HSPGs.
Discussion
Gliomedin was isolated as a glial ligand for neurofascin and   
NrCAM, which are two immunoglobulin CAMs that associate 
with Na
+ channels at the nodes of Ranvier (Eshed et al., 2005). 
It was shown that immunopatching the olfactomedin domain of 
Figure 6.  Removal of gliomedin from Schwann cell ECM by heparin. (A and B) Binding of Fc-fusion protein containing the extracellular domain of neuro-
fascin (NF155-Fc; red) to ascorbic acid–treated rat Schwann cells (A), or after incubation of the ascorbic acid-treated cells with heparin (B). (C and D) 
NF155-Fc still bound to gliomedin that is present in the ECM after removing the cells with ammonium hydroxide and Triton X-100 (C), but not after prior in-
cubation of the slides with heparin (D). Nuclei are labeled with DAPI (blue). (E–J) Heparin treatment removed gliomedin, but not α4(V), from the ECM. 
NF155-Fc binding (red) to ascorbic acid–treated Schwann cells, without (E) or with (H) preincubation of the cells with heparin. Cells were then ﬁ  xed and 
immunolabeled with an antibody to α4(V) collagen (F and I; green), and the merged images are shown in G and J. (K–M) The transmembrane form of glio-
medin mediates binding of NF155-Fc to Schwann cells after heparin treatment. NF155-Fc binding to ascorbic acid and heparin–treated rat Schwann cells 
(K; red). Cells were then ﬁ  xed, permeabilized, and immunolabeled with an antibody 836 directed to the intracellular domain of gliomedin (L; green). 
Schwann cells nuclei were labeled with DAPI (blue). The merged image is shown in M. Bars: (A–J) 30 μm; (K–M) 15 μm.JCB • VOLUME 177 • NUMBER 3 • 2007  558
gliomedin on DRG neurons induced the clustering of these two 
axonodal CAMs and the assembly of nodal-like clusters con-
taining Na
+ channels, ankyrin G, and βIV spectrin (Eshed et al., 
2005). In the present work, we report that gliomedin shares 
several characteristics with collagenous transmembrane proteins 
that may account for its clustering activity. We demonstrate that 
the majority of gliomedin exists as a secreted protein, which 
forms multimers that are further incorporated into the Schwann 
cell ECM by binding to HSPGs (Fig. 8). We suggest that the 
  entrapment of gliomedin within the perinodal space surrounding 
the Schwann cell microvilli creates an arrayed matrix of multi-
ple binding sites for the axonodal CAMs that drives an effi  cient 
clustering of these CAMs on the axolemma.
Secreted forms of gliomedin
The domain architecture of gliomedin resembles that of col-
lagenous transmembrane proteins, which are a growing group 
of type II transmembrane proteins that function as cell sur-
face receptors and matrix components (Franzke et al., 2005; 
Myllyharju and Kivirikko, 2004). Most of the collagenous trans-
membrane proteins are shed from the cell surface by furin or a 
furin-dependent proteolytic cleavage (Franzke et al., 2005). 
We found that medium conditioned by Schwann cells con-
tained two soluble fragments of gliomedin, indicating that two 
distinct cleavage sites are present in its extracellular domain. 
Gliomedin contains four basic amino acids RNKR at position 
91–94 between the transmembrane and collagen domains that 
match the consensus site for furin, which is a proprotein conver-
tase that cleaves after the C-terminal arginine residue in the se-
quence R-X-K/R-R (Thomas, 2002). Mutating the two arginines 
at position 91 and 94, resulted in a marked reduction in the 
  secretion of gliomedin to the medium, suggesting that, similar 
to other collagenous transmembrane proteins, gliomedin is pro-
cessed by a furinlike enzyme. Immunolabeling rat sciatic nerves 
using antibodies to different regions of the molecule demon-
strated that the transmembrane form of gliomedin is completely 
absent from nodes, indicating that the processing of gliomedin 
also occurs in vivo. The fi  nding that only the cleaved form of 
gliomedin is present at nodes is further supported by previous 
immunoelectron microscopy data showing that gliomedin 
immunoreactivity was also present between the microvilli at the 
nodal gap (Eshed et al., 2005). At present, it is not clear whether 
the furin-dependent processing of gliomedin occurs in the trans-
Golgi, at the cell surface, or at both sites, as was recently dem-
onstrated for collagen XIII (Vaisanen et al., 2006).
The N-terminal sequence of the smaller gliomedin frag-
ment found in the medium of transfected HEK-293 cells un-
equivocally identifi  ed as DDTLVG, demonstrating that the second 
cleavage of gliomedin occurs between asparagine 277 (N277) 
and aspartic acid 278, which is located N-terminal to the olfacto-
medin domain. This sequence corresponds well to the known 
cleavage site of the bone morphogenetic protein / Tolloid-like 
metalloproteinases, which process several collagens, as well as 
a variety of other ECM proteins (Ge and Greenspan, 2006). 
However, it should be emphasized, that the major proteolytic 
product of gliomedin detected in Schwann cell medium was the 
91-kD fragment containing both the collagen and the olfacto-
medin domains. In contrast, we detected only a small amount of 
the 45-kD olfactomedin fragment in Schwann cell media grown 
for long periods of time in culture, indicating that the second 
proteolytic cleavage is much less common. In support, we did 
not detect the 45-kD protein in the medium of astrocytes and we 
could not extract it from nerve lysates (unpublished data).
Multimers of gliomedin are required 
for its interaction with the axonodal CAMs
Previous experiments have demonstrated that the olfactomedin 
domain of gliomedin mediates its interaction with neurofascin 
or NrCAM (Eshed et al., 2005). We extend these fi  ndings and 
note an important difference between the ability of the olfacto-
medin domain to bind neurofascin as a single domain (OLF), or 
as part of the entire extracellular domain of  gliomedin (ECD). 
We show that although ECD-Fc could bind to neurofascin as a 
soluble dimer (dimers are enforced by the Fc tag), binding of 
OLF-Fc required its multimerization with a secondary antibody. 
Thus, it appears that specifi  c multimerization sequences outside 
the OLF domain are critical for the interaction between glio-
medin and the axonodal CAMs. The extracellular region of glio-
medin also includes a collagen-like domain, which contributes 
to the multimerization of gliomedin by forming triple helices 
(Gelse et al., 2003). Several experimental observations support 
this possibility. First, mass spectrometry analysis showed that 
Figure 7.  Heparin-dependent binding of gliomedin to Schwann cells. (A–D) 
Heparin inhibits the interaction of gliomedin with Schwann cells and 
Schwann cell ECM. Binding of an Fc-fusion protein containing the extra-
cellular domain of gliomedin (ECD-Fc; red) to Schwann cells grown in the 
absence (A and B) or presence (C and D) of ascorbic acid. Schwann cell 
nuclei were labeled with DAPI (blue). Preincubation of the cells with hepa-
rin abolished the binding of ECD-Fc to both Schwann cells and the ECM 
(B and C). (E) Gliomedin is a heparin-binding protein. Medium containing the 
Fc-fusion proteins indicated on top was incubated with protein A–agarose 
(PA) or heparin–Sepharose beads (HS). Precipitated material was resolved 
on an SDS gel, followed by immunoblotting with an antibody to human Fc. 
An Fc-fusion protein of myocilin was used as a control. The location of 
  molecular weight marker is shown on the right in kilodaltons. Bars, 30 μm.GLIOMEDIN IS A PERINODAL MATRIX COMPONENT • ESHED ET AL. 559
the collagen domain of gliomedin is resistant to digestion by 
trypsin and chemotrypsin (unpublished data), which are a com-
mon characteristic of collagen triple helices (Bruckner and 
Prockop, 1981). Second, using a chemical cross-linker (BS
3), 
we demonstrated that gliomedin is found as trimers in Schwann 
cells treated with ascorbate, which is known to stimulate prolyl-
hydroxylation of collagens, which is required for the formation 
of intramolecular hydrogen bonds and stabilization of their 
  triple helical conformation (Trackman, 2005). Furthermore, we 
also detected multimers of gliomedin, suggesting that the 
formed homotrimers may be further assembled into higher-
  order structures that are similar to various collagens (Myllyharju 
and Kivirikko, 2004). Third, and in keeping with the latter pos-
sibility, we found that treatment of Schwann cells with ascorbic 
acid markedly reduced the solubility of gliomedin. Finally, we 
show that gliomedin undergoes self-association, which is medi-
ated by the N-terminal region of the protein and is required for 
its interaction with the axonodal CAMs. Gliomedin contains a 
juxtamembrane α-helical, coiled-coil sequence at position R42-
E61, which, in transmembrane collagens, directs correct chain 
association and initiates a zipperlike folding of the triple helix 
(Latvanlehto et al., 2003; McAlinden et al., 2003). Self-association 
of gliomedin was reduced by the deletion of this coiled-coil 
sequence, but was almost completely abolished when the entire 
N-terminal domain was deleted. This result indicates that al-
though the juxtamembrane coiled-coil sequence may facilitate 
trimerization, adjacent noncollagenous sequences within the 
N-terminal domain are required for the recognition and associa-
tion of gliomedin monomers. In keeping with such a role, we 
found that binding of a soluble extracellular region of glio-
medin lacking the N-terminal domain (ECDdNTR-Fc) to neuro-
fascin required its multimerization.
Incorporation of gliomedin into Schwann 
cell ECM
Previous immunofl  uorescence and immunoelectron microscopy 
analyses of peripheral nerves demonstrated that gliomedin is 
localized to the nodes of Ranvier (Eshed et al., 2005). The fi  nd-
ing that gliomedin is a secreted protein, thus, poses an impor-
tant question as to how it is concentrated at the nodal gap. 
Binding experiments using mixed Schwann cells/neuron cul-
tures showed that a secreted extracellular domain of gliomedin 
binds to both cell types. Although the olfactomedin domain 
mediated its binding to neurons, the N-terminal and collagen 
domains of gliomedin were required for its interaction with 
Schwann cells, suggesting the existence of another ligand for 
gliomedin at the perinodal space. Using isolated rat Schwann 
cells, we demonstrated that the extracellular domain of glio-
medin binds to Schwann cell ECM. Moreover, we found 
that endogenous gliomedin secreted from Schwann cells was 
 incorporated into fi  brillar matrix deposits that were labeled for 
collagen V, laminin, and perlecan. We also showed that a solu-
ble extracellular domain of neurofascin strongly bound to these 
matrix deposits, indicating that the embedding of gliomedin 
within the ECM does not diminish its ability to interact with the 
axonodal CAMs. These results suggest that gliomedin is a spe-
cifi  c component of the Schwann cell perinodal matrix, which 
was originally described by Ranvier as the cement disc (Landon 
and Hall, 1976). This conclusion is further supported by the re-
cent identifi  cation of gliomedin as an ECM protein synthesized 
by follicular papilla, which is a group of specialized mesenchy-
mal cells in the hair follicle (Cao et al., 2005). It is also of 
  interest to note that all of the known olfactomedin-containing 
proteins have been identifi  ed as ECM proteins (Snyder et al., 
1991; Bal and Anholt, 1993; Yokoe and Anholt, 1993; Hillier 
and Vacquier, 2003; Zeng et al., 2004; Ando et al., 2005; Furutani 
et al., 2005), which, similarly to gliomedin, have restricted 
tissue distributions and thus may comprise a unique subgroup 
of ECM elements as recently suggested (Liu et al., 2006).
The accurate deposition of many ECM proteins is often 
regulated by their binding to HSPGs (Bernfi  eld et al., 1999). We 
showed that the binding of exogenous gliomedin to Schwann 
cells was inhibited by heparin, suggesting that it binds HSPGs. 
In agreement, incubation of ascorbate-treated Schwann cells 
with heparin completely removed gliomedin from the ECM. 
We also showed that the extracellular domain of gliomedin di-
rectly bound to heparin–Sepharose through its collagen domain. 
Consistent with this observation are two putative heparin-binding 
sequences located in the collagen-like domain of gliomedin 
(amino acid positions 176 and 253), both composed of a BBXB 
motif (where B represents a basic residue). Several HSPGs were 
shown to be expressed by Schwann cells, including syndecans 
(Carey et al., 1992), perlecan and glypican (Rothblum et al., 
2004), agrin (Yang et al., 2001), and collagen XVIII (Halfter 
et al., 1998), of which only syndecans were shown to be present 
at the nodes of Ranvier (Goutebroze et al., 2003; Melendez-
Vasquez et al., 2005). Whether gliomedin interacts with any of 
these HSPGs, and whether such interaction is important for its 
localization at nascent nodes, is of great interest and will be de-
termined in future studies.
Figure 8.  A proposed model for the accumu-
lation of gliomedin at nodes. Gliomedin is syn-
thesized in the ER (A), followed by trimerization 
of the collagen domain, which forms a triple 
helical conﬁ  guration that subsequently appears 
on the plasma membrane (B). Cleavage of 
gliomedin trimers occurs at the cell surface by 
furin, releasing it to the medium (C). Cleavage 
of gliomedin may also occur at the trans-Golgi 
network (not depicted). (D) Secreted gliomedin 
accumulates at the perinodal space by bind-
ing to HSPGs, creating a local high concen-
tration that interacts with and clusters the 
axonodal CAMs.JCB • VOLUME 177 • NUMBER 3 • 2007  560
Implications on nodes formation
The accumulation of Na
+ channels at the nodes of Ranvier in the 
PNS depends on the presence of myelinating Schwann cells and 
requires the interaction of these channels with NrCAM and neu-
rofascin, as well as with βIV spectrin and the cytoskeletal adap-
tor protein ankyrin G (Kordeli et al., 1995; Berghs et al., 2000; 
Malhotra et al., 2000; Ratcliffe et al., 2001; Komada and Soriano, 
2002; Custer et al., 2003; Lemaillet et al., 2003; Sherman et al., 
2005). It was previously suggested that these channels are being 
recruited by ankyrin G to the axonodal CAMs, which were fi  rst 
clustered by gliomedin present on glial processes that contact the 
nodal axolemma (Eshed et al., 2005; Schafer and Rasband, 
2006). Based on our current results demonstrating that glio-
medin is a secreted protein, one should consider a modifi  cation 
of this model. Thus, we propose that during the development of 
peripheral nerves, gliomedin is released from the cell surface by 
proteolytic cleavage and is then entrapped at the edges of my-
elinating Schwann cells by HSPGs that are enriched at these 
sites. Binding of gliomedin to HSPGs may serve two purposes. 
First, it would allow the buildup of a tremendously high local 
concentration of gliomedin at the nodal gap, and second, it would 
create a meshlike array of gliomedin that would facilitate high 
avidity binding and further clustering of neurofascin and NrCAM 
present on the axolemma. Heparan sulfate glycosaminoglycan 
residue could be provided by transmembrane syndecans that are 
present on microvilli processes, as well as by secreted HSPGs 
that are found at the basal lamina overlaying the nodal gap. In 
keeping with the latter possibility, it has recently been demon-
strated that the composition of the basal lamina at the nodes is 
different from that of the internodal region and contains specifi  c 
ECM components, such as laminin α5β1γ2 (Occhi et al., 2005). 
Alternatively, gliomedin may interact with secreted HSPGs, such 
as perlecan, which would be immobilized at the nodal gap by 
dystroglycan that is present on the Schwann cell microvilli and is 
required for the normal clustering of nodal Na
+ channels (Saito 
et al., 2003; Occhi et al., 2005). Once accumulated at the nascent 
nodes, gliomedin multimers would avidly bind to and induce the 
clustering of the axonodal CAMs, thereby facilitating the assem-
bly of nodal complexes containing Na
+ channels.
Materials and methods
Tissue culture methods
Dissociated rat DRG cultures were grown in Neurobasal medium (Invitro-
gen) supplemented with B27 (Invitrogen) and 50 ng/ml NGF (Neurobasal 
medium; Alomone Labs) for 5 d before being used in binding experiments. 
Puriﬁ   ed DRG neurons were established by treating dissociated mixed 
cultures with two cycles (2 d each) of NB medium containing 10 μM 
uridine/10 μM 5′-Fluoro 2’-deoxyuridine (Sigma-Aldrich) to eliminate 
ﬁ  broblasts and Schwann cells. Schwann cells isolated from P4 rat sciatic 
nerve were grown in Schwann cell proliferation medium (DME, 3% FBS, 
10% NDFβ conditioned medium, 2 μM forskolin, 2 mM glutamine, and 
1 mM pyruvate) on primaria culture dishes (Falcon). To stimulate ECM 
  assembly, Schwann cells were treated with 50 μg/ml L-ascorbic acid 
(Sigma-Aldrich) for 48 h. To remove cells from the culture dish, cultures were 
treated with PBS + 0.5% Triton X-100 and 20 mM ammonium hydroxide 
for 10 s and subsequently washed with PBS.
Constructs, recombinant proteins, and antibodies
Gliomedin Fc fusions COL-Fc (residues 49–294), OLF-Fc (residues 288–543), 
ECD-Fc (residues 49–543), and NF155-Fc were previously described 
(Eshed et al., 2005). Fc fusions ECDdNTR-Fc and ECDdCC-Fc (residues 
139–543 and 62–543, respectively) were generated by cloning the corre-
sponding cDNA to pSX-Fc. Myocilin-Fc was generated by cloning full-length 
myocilin ampliﬁ  ed by PCR from rat Schwann cell cDNA into pCX-Fc. Gener-
ation of the mutant proteins gliomedin R91G and R94A was done using the 
5′ primers C  C  C  A  T  G  A  G  T  G  C  A  G  C  C  G  G  C  A  A  T  A  A  G  C  G  A  G  C   (for R91G, NaeI 
site was inserted), and G C  A  G  C  G  C  G  C  A  A  T  A  A  G  G  C  T  A  G  C  C  A  C  G  G  C  G  G  C  G-
A  G   (for R94A, NheI site was inserted) and their complementary 3′ primers. 
PCR was performed using Pfu DNA Polymerase (Promega) on pRKpF10 
(Eshed et al., 2005) as a template, followed by a DpnI digestion.
Polyclonal and monoclonal antibodies to gliomedin (Ab720 and 
mAb94) were previously described (Eshed et al., 2005). Polyclonal anti-
body 320 was generated by immunizing rabbits with the aforementioned 
puriﬁ  ed recombinant protein OLF-Fc. Polyclonal antibody 836 was gener-
ated against a synthetic peptide corresponding to residues 1–16 that com-
prise the cytoplasmic tail of gliomedin. Polyclonal antibodies to α4(V) and 
to α1(V) were obtained from David Carey. Rabbit anti–laminin antibody 
was purchased from Sigma-Aldrich.
Fc-binding and immunoﬂ  uorescence
Cells were grown on poly-L-lysine–coated (Sigma-Aldrich) coverslips. For 
binding experiments, conditioned media containing various Fc-fusions 
were either mixed with a Cy3-conjugated anti–human Fc antibody for 30 
min before the binding procedure or were not mixed (“nonclustered”). After 
a 30-min incubation of the cells with the conditioned media at RT, cells were 
washed and ﬁ  xed with 4% PFA for 5 min at RT. In the case of nonclustered 
binding, coverslips were incubated with a Cy3-conjugated anti–human Fc 
antibody after ﬁ  xation for 30 min at RT. For antibody labeling, cells were 
ﬁ   xed in 4% PFA, washed with PBS, and incubated in blocking solution 
(PBS, 10% normal goat serum, 0.1% Triton X-100, 1% glycine) for 30 min. 
Primary antibodies diluted in blocking solution were added for 1 h at RT, 
followed by washing with PBS and incubation with secondary antibodies 
diluted in blocking solution for 40 min. Coverslips were then washed, 
mounted in elvanol, and analyzed on a microscope (Eclipse E1000; Nikon; 
objectives 20×/0.5 NA, 40×/1.3 NA, and 60×/1.4 NA) equipped with 
a camera (ORCA-ER; Hamamatsu). Fluorescence images were acquired us-
ing Openlab software (Improvision) and ﬁ  gures were mounted using Photo-
shop software (Adobe). In the case of laminin and collagen V staining, live 
cultures were incubated with primary antibodies for 45 min, followed by 
washing and ﬁ   xing. Secondary antibodies were added after a 30-min 
blocking as described for nonclustered cells. To assess the effect of heparin 
on the gliomedin labeling, Fc fusion binding or antibody labeling were 
performed after a 30-min treatment with 10 μg/ml heparin in PBS supple-
mented with Ca
2+ and Mg
2+. Teased sciatic nerves were prepared and 
  immunolabeled as previously described (Eshed et al., 2005).
Immunoprecipitation, pull-down, and immunoblot analysis
For immunoprecipitation, Schwann cells or transfected cell conditioned 
  media and cell extracts (lysed in 50 mM Hepes, pH 7.2, 150 mM NaCl, 
1 mM EGTA, 10% glycerol, 1% Triton X-100, 2 mM PMSF, and 10 μM apro-
tinin and leupeptin) were immunoprecipitated by polyclonal anti-gliomedin 
antibodies cross-linked to protein A–Sepharose beads using Dimethyl Pime-
limidate (Sigma-Aldrich). Samples were analyzed by electrophoresis on 
10% polyacrylamide SDS gels. For cross-linking experiments, Schwann 
cells were treated with BS
3 (Pierce Chemical Co.) according to manufactur-
er’s protocol before cell lysis. Cell extracts were subjected to the afore-
mentioned immunoprecipitation. To asses the solubility of gliomedin after 
ascorbate treatment, immunoprecipitation was performed in an SDS-free 
RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% 
  Na-deoxycholate, 1 mM EDTA, 2 mM PMSF, and protease inhibitors) or in 
a RIPA buffer containing 0.1% SDS. For pull-down experiments, protein A 
beads bound with various gliomedin Fc-fusion proteins were mixed with cell 
extracts of HEK-293T cells transfected with either gliomedin-myc or PSD93-
myc as control, for 4 h at 4°C. Beads were subsequently washed and ana-
lyzed by electrophoresis and immunoblot using anti-myc antibodies. For 
heparin pull-down experiments, conditioned media of various gliomedin 
Fc-fusion proteins and myocilin-Fc were mixed with either protein A–Sepharose 
or heparin–Sepharose beads for 1 h at RT. Beads were subsequently washed 
and resolved by electrophoresis and immunoblot using anti–human anti-
bodies. N-terminal sequencing of a secreted Fc-tagged gliomedin was deter-
mined using Procise 491 protein sequencer (Applied Biosystems).
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